Indeed, in the phase I/II AURA trial for patients with advanced NSCLC progressing during treatment with 1G/2G EGFR-TKIs, the median PFS on osimertinib was 9.6 and 2.8 months in T790M-positive and -negative cases, respectively [93]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.